TLS Detect
RUO
Tertiary Lymphoid Structures
Clinical context
The potential of TLS in oncology research
Research shows TLS plays a crucial role in oncology by providing insights into the tumor's interaction with the immune system.*
Benefits of TLS detection
TLS presence is considered a novel biomarker to stratify the overall survival risk of untreated cancer patients and as a marker of efficient immunotherapy treatment.
A simple and standardized approach to measure TLS from routine digitised H&E slides could support the adoption of this biomarker as an independent predictor of response to immune checkpoint inhibitors (ICI).
With a sensitivity of 97%, TLS Detect has the potential to screen for TLS presence in tumors in a research setting.
In a research setting
Determine the status of TLS
Sample
Tissue sample is taken and prepared as H&E slide
Digitization
H&E slide digitized
AI solution
TLS Detect extracts and analyzes features from the digitized slide
TLS Detect
PDF Report with dynamic heat map
Results
Results
TLS
Presence of TLS, with analysis score provided
No TLS
No presence of TLS, with analysis score provided
Citations
- Vanhersecke et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer Vol 2 794-802 (Aug 2021)
- Srivastava et al. IMpower110: Tertiary lymphoid structures and clinical outcomes in advanced non-small cell lung cancer treated with first-line atezolizumab or chemotherapy. Presented at The Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. (November 2023).
**97% sensitivity was achieved through validation on an external dataset (n=157 patients)